A-Alpha Bio raises $2.8m from venture capital firms and angel investors to further develop its technology – and initiate drug discovery and optimization partnerships with pharmaceutical companies.
To improve patient safety and reduce risk, Elsevier is developing an improved drug-drug interaction risk calculator in collaboration with several pharma partners, including Boehringer Ingelheim, Eli Lilly, and Servier.
Almac joins a working group made up of clinical supply chain industry members, in order to contribute to the use case discussion about blockchain technology.
InsightRX raises $10m in a Series A funding round to further develop its treatment individualization platform and broaden the therapeutic areas in which it’s applicable.
‘Talk to your CDMO early’ is the advice BioConnection gives to developers of biopharmaceuticals, suggesting that they make a reservation to ensure availability.
PPD is expanding its immunochemistry and biomarker space by 8,000 square feet, the addition of which will also support a dedicated team for one of the company’s global biopharmaceutical clients.
Signant Health is piloting the use of eConsent in a ‘landmark’ study in China, the successful completion of which will encourage further adoption of the technology across the Asia Pacific region, says VP.
Torrent announces that it will recall batches of losartan tablets for the sixth time, after the detection of NMBA exceeding acceptable daily intake levels in latest recall.
Insilico Medicine brings in $37m to further develop its artificial intelligence work after publishing a study that demonstrates the ‘real-world potential’ of AI for drug discovery – moving the idea from theory to reality.
As a day of climate strikes unfolds across the world, we ask how far pharma is engaged on the issue, as well as noting recent innovations that suggest companies are looking at what can be done.
Bayer collaborates with Accenture on the Intient clinical platform, which integrates internal and external clinical data to accelerate drug development insights.
In response to demand for flexibility, Cromsource has consolidated its hybrid services model to provide customers with an alternative to fully outsourced or functional service provider (FSP) models.
The digital health company AMRA has entered into an exclusive agreement with the largest imaging CRO in Japan as part of its work to provide ‘critical informatics’ to the drug development industry.
Darmerica recalls two lots of product labeled as quinacrine, a compound used as a sclerosing agent, which were instead found to contain a treatment for malaria.
There has been a lot of discussion surrounding the use of artificial intelligence in drug development – with several deals, alliances, and partnerships made so far this year. Here, Outsourcing-Pharma takes a look back at some of these announcements, as...
BIA Separations introduces technology able to remove host-cell DNA and proteins from AAV products, aiming to accelerate clinical development of gene therapies.
hyperCore International is the first site network to receive the ‘Virtual Trial Capable’ certification after completing VirTrial’s recently launched training program.
Aetion today announced that former FDA Commissioner Scott Gottlieb has joined its board of directors to help to advance the use of RWE in drug development and commercialization.
Shimmer Research launches an initiative to develop a set of open-source algorithms and software tools for analyzing wearable sensor data – and, ultimately, standards that will be accepted by industry and regulators.
Both the FDA and EMA announce NDMA contamination of ranitidine medicines and a lawsuit is immediately filed against manufacturers for ‘concealing’ the carcinogen.
Merz announces that it has completed the construction of a new plant for its botulinum neurotoxin product and unveils a ‘robot-controlled’ filling line.
Medidata is building a global library of pre-configured, pre-approved eCOA questionnaires to accelerate study start-up in collaboration with Icon's Mapi Research Trust – “a win-win-win” for all involved.
Purdue reaches agreement to settle opioid litigation it is facing in the US by pursuing bankruptcy and providing a suggested $10bn towards the opioid crisis.
Clinerion is deploying Volv’s AI algorithms across its hospital network as part of a recently announced strategic collaboration that includes plans to bring an ‘enhanced value proposition’ to both companies’ expanded client base, says CEO.
The drug discovery and preclinical services company has moved its US office to Kendall Square as it looks to ‘sustainably grow’ its US presence and increase sales in the coming years, says SVP.
South Korea looks to accelerate review timelines and study start-up with a new five-year plan that will benefit biotechs looking for locations outside the US to ‘ramp up’ clinical development programs, says CRO.
In response to the UK government’s publication of potential ramifications of a no-deal Brexit, the ABPI responded that the pharma industry needs more details on mitigation strategies.
The pharmaceutical and biotech product development consultancy Boyds acquires Blue Duck Consulting to boost its clinical and medical affairs services offering.
Civica agrees a deal with Exela to secure the supply of sodium bicarbonate injections to distribute through its hospital network due to ‘ongoing shortages’.
The FDA has extended its agreement with CluePoints to augment the agency’s oversight of clinical trials using data-driven approaches, with additional testing ideas focusing on moderators of treatment effect and real-world evidence, says CCO.
Incorporating patient insights into clinical trial design has ‘consistently’ shown to improve timelines, though this requires involvement from all stakeholders, including physicians, who on average spend only 17.5 minutes with a patient during a single...
Patients often feel more comfortable sharing their feelings with a device than with a health care provider, found researchers at Janssen, who have developed a new voice technology application for clinical trials.
Javara, Elligo Health Research, and Circuit Clinical are leading ‘a monumental shift’ in how clinical trials are conducted through the ‘integrated research organization’ model, which is taking on traditional approaches challenged by ‘participant scarcity’...
From pilot projects to process changes, the evolution of patient centricity is affecting all aspects of drug development, say industry experts, who share best practices and lessons learned.
After ‘holding its breath’ for nearly half a decade, pharma and health care companies are ready to implement new technology in clinical trials – though data standardization will be key to fully realizing the benefits.
